A clinical study suggests that the AURKA inhibitor Alisertib could be also combined with paclitaxel as a second-line treatment for SCLC, and patients in the Alisertib/paclitaxel group have shown good efficacy25. Here, AURKA is linked to small cell lung carcinoma.